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Abstract
Background: Mutations of the NR5A1 gene encoding steroidogenic factor-1 have been reported in association with a wide
spectrum of 46,XY DSD (Disorder of Sex Development) phenotypes including severe forms of hypospadias.
Methodology/Principal Findings: We evaluated the frequency of NR5A1 gene mutations in a large series of patients
presenting with 46,XY DSD and hypospadias. Based on their clinical presentation 77 patients were classified either as
complete or partial gonadal dysgenesis (uterus seen at genitography and/or surgery, n=11), ambiguous external genitalia
without uterus (n=33) or hypospadias (n=33). We identified heterozygous NR5A1 mutations in 4 cases of ambiguous
external genitalia without uterus (12.1%; p.Trp279Arg, pArg39Pro, c.390delG, c140_141insCACG) and a de novo missense
mutation in one case with distal hypospadias (3%; p.Arg313Cys). Mutant proteins showed reduced transactivation activity
and mutants p.Arg39Pro and p.Arg313Cys did not synergize with the GATA4 cofactor to stimulate reporter gene activity,
although they retained their ability to physically interact with the GATA4 protein.
Conclusions/Significance: Mutations in NR5A1 were observed in 5/77 (6.5%) cases of 46,XY DSD including hypospadias.
Excluding the cases of 46,XY gonadal dysgenesis the incidence of NR5A1 mutations was 5/66 (7.6%). An individual with
isolated distal hypopadias carried a de novo heterozygous missense mutation, thus extending the range of phenotypes
associated with NR5A1 mutations and suggesting that this group of patients should be screened for NR5A1 mutations.
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Introduction
The term Disorders of Sex Development (DSD) has been
defined as ‘congenital conditions in which the development of
chromosomal, gonadal, or anatomical sex is atypical.’ Therefore
DSD constitutes a spectrum of disorders that affect the genito-
urinary tract and the endocrine-reproductive system [1]. 46,XY
DSD includes the conditions of 46,XY partial or complete gonadal
dysgenesis, and undervirilisation or undermasculinization of an
XY male. Some of these phenotypes, such as 46,XY gonadal
dysgenesis are relatively rare, whereas the 46,XY DSD related
phenotype hypospadias is a relatively common congenital anomaly
with an estimated incidence of 1:200–1:300 live births [2].
The etiology of hypospadias is unknown in most cases. Only
approximately 5% of all cases of hypospadias are explained by rare
genetic anomalies of androgen biosynthesis or androgen receptor
[2]. Mutations in genes expressed in the developing male gonad
including MAMLDL1 or mutations in genes that are associated with
syndromic forms of hypospadias such as HOXA13 are rare [3], [4].
A few genetic associations have been reported, but these involved
small cohort sizes and most of these studies have not been replicated
[5], [6]. Although environmental factors may contribute to the
formation of hypospadias in utero and may be linked with the
proposed increase in the incidence of hypospadias in some Western
countries [7], [8], the familial aggregation that is often associated
with hypospadias suggests a genetic component [9].
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e24117The gene NR5A1, which encodes steroidogenic factor-1, is a
pivotal transcriptional regulator of genes involved in the
hypothalamic-pituitary-steroidogenic axis [10], [11]. During early
male development NR5A1 positively regulates the expression of
two key genes involved in male sex determination and differen-
tiation, SOX9 (Sry-box 9), and Anti-Mu ¨llerian Hormone (AMH)
[12], [13]. NR5A1 also modulates the expression of many factors
involved in cholesterol mobilization and steroid hormone
biosynthesis including HMG-CoA synthase, steroidogenic acute
regulatory protein (StAR), 3b-hydroxysteroid dehydrogenase
(3bHSD), and several cytochrome P450 steroid hydroxylase
(CYP) enzymes [14]. The NR5A1 protein consists of a DNA-
binding domain (DBD) of two zinc fingers, a hinge region, a
ligand-binding domain (LBD), and two activation function
domains [15]. NR5A1 is expressed in the Sertoli and Leydig cells
of the developing testis and in Sertoli cells of the prepubertal and
adult testis [16], [17]. Mice lacking Nr5a1 show both gonadal and
adrenal agenesis [11]. Human NR5A1 mutations were first
reported in association with 46,XY DSD and adrenal insufficiency
and in a 46,XX girl with adrenal insufficiency [14], [18]. More
recently, the range of phenotypes that are associated with NR5A1
mutations has broadened and now includes 46,XY complete and
partial gonadal dysgenesis, penoscrotal hypospadias, microphallus
with anorchidia and 46,XX primary ovarian insufficiency (POI)
[15], [19]–[21]. In all of these more recent cases, there is no
evidence of adrenal insufficiency. In a large study on hypospadias,
it was concluded that heterozygous loss-of-function mutations in
NR5A1 could be found in severe forms of hypospadias, but not
found frequently in association with minor forms of hypospadias
[19].
In this study, we evaluated the frequency of NR5A1 gene
mutations in a large series of 46,XY DSD cases with phenotypes
that ranged from complete gonadal dysgenesis to simple
hypospadias. All cases showed no evidence of adrenal insufficien-
cy. Five heterozygous NR5A1 mutations were identified that were
not observed in control individuals. Functional studies indicated
altered biological activity for the mutant NR5A1 proteins. A de
novo heterozygous mutation was identified in one individual with
simple distal hypospadias. This extends the range of phenotypes
associated with mutations in NR5A1.
Materials and Methods
Patient Recruitment
This retrospective study was performed on 77 patients, first seen
from birth to 17 years of age, between 1981 and 2008 in a
university pediatric hospital by one of us (R Brauner) for 46,XY
DSD, including hypospadias.
The 77 patients were classified as complete or partial gonadal
dysgenesis (uterus seen at genitography and/or surgery, n=11),
ambiguous external genitalia without uterus (n=33) and hypo-
spadias (n=33). The patients classified as hypospadias had a
normal penis length [greater than 30 mm, 22 SD, 21] and
palpable inguinal or intrascrotal gonads bilaterally (n=28) or
unilaterally (n=5). The meatus location was penoscrotal (n=2),
mid-shaft (n=3) or glandular (n=10).
Clinical examination included palpation of the labioscrotal and
inguinal areas for the consistency of the gonads. Internal genitalia
were evaluated by pelvic ultrasound examination and/or genito-
graphy. Associated abdominal ultrasound examination was carried
out to assess kidney malformations. Several patients were given
testosterone heptylate (46100 mg/m
2 given im every 15 days) in
the neonatal period before the sex assignement and/or before the
genitoplasty. For each patient, cytogenetic analysis was performed
on peripheral blood leukocytes. The chromosome complement
was determined by examining 40 to 50 metaphases from each
patient. The endocrine evaluation was conducted to assess
congenital adrenal hyperplasia and failure, testosterone biosyn-
thesis by normal adrenocorticotropin hormone, cortisol, 17OH-
progesterone, 11-deoxycortisol, dehydroepiandrosterone, and D4
androstenedione plasma concentrations. Leydig cell function was
evaluated by measuring the basal plasma testosterone concentra-
tion and after stimulation with human chorionic gonadotropin
(hCG, 3 or 761,500 IU) with samples taken the day after the last
injection. In general, the hCG test was not performed in the
patients with basal plasma testosterone concentration greater than
1 mg/L or with basal plasma luteinising hormone (LH) concen-
tration greater than 5 IU/L. 5 a-re ´ductase deficiency was
investigated by measuring the testosterone/dihydrotestosterone
ratio in basal situation or after stimulation with hCG. Aliquots of
plasma were frozen at 220uC in the more recent patients to
measure AMH (n=58) and inhibin B (n=45) and compared to
the normal range for age [22], [23]–[26]. Plasma AMH was
measured using the AMH/Mullerian-inhibiting substance ELISA
kit (Immunotech-Beckman, Marseille, France). Plasma inhibin B
levels were measured by ELISA using Oxford Bio-Innovation
reagents (Diagnostic Systems Laboratories-France, Cergy-Pon-
toise, France). According to the manufacturer, sensitivity of the
assay was 15 pg/ml; at a mean concentration of 100 pg/ml, the
intra- and interassay coefficients of variation were less 6% and
16% respectively. Serum testosterone levels were measured by
RIA after extraction using Orion reagents (Cis biointernational,
Gif-sur-Yvette, France). Plasma LH and follicle stimulating
hormone (FSH) levels were measured with an IRMA assay
(Immunotech- Beckman, Marseille, France) with a sensitivity of
0.2 UI/L. The intra- and interassay coefficients of variation were
less 6.7% in both gonadotropin assay. Conventional histological
examination of the gonads was performed after gonadectomy of
patients reared as females or following a gonadal biopsy (n=12).
Ethics Statement
This study was approved by the institutional review board and
the local ethics committee (Comite ´ de Protection des Personnes,
Ile de France, III). Written, informed consent was given by all the
parents for the evaluation including chromosomal and molecular
biology analyses, and surgery.
DNA analysis and Functional studies
Genomic DNA was extracted from peripheral blood leukocytes
by standard procedures. The NR5A1 gene was amplified and
sequenced as described elsewhere [20]. NR5A1 expression vectors
containing the p.Arg39Pro and p.Arg313Cys variants were
generated by site-directed mutagenesis (QuikChange, Stratagene)
using wild-type (WT) human NR5A1 cDNA in a pCMX
expression vector as a template. Mouse full-length GATA4 cDNA
was excised by digesting GATA4-GST vector (a gift from J. D.
Molkentin, Cincinnati Children’s Hospital Medical Center,
Cincinnati) with EcoRI restriction endonuclease (New England
Biolabs). The cDNA was then cloned in EcoRI-digested pIRES-
hrGFP II vector (Stratagene). As a control the p.Gly35Glu NR5A1
mutant protein in vector in the expression pCMX was used (a gift
from Dr J. C. Achermann, University College London, U.K.) [18].
The entire coding sequence of all mutant plasmids was confirmed
by direct sequencing prior to functional studies. Transient gene
expression assays to assess NR5A1 function were performed in 96-
well plates (TPP) using human embryonic kidney cells HEK 393-
T, FUGENE 6 (Roche), and a Dual-Luciferase reporter assay
system (Promega) with pRLSV40 Renilla luciferase (Promega)
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NR5A1 expression vectors (2 ng/well) were co-transfected into
HEK 293-T cells with reporters containing SF1 responsive
minimal promoters (murine Cyp11a1, human AMH; 10 ng/well)
[27], [28]. Cells were lysed 24 hours later and luciferase assays
were performed (Dual Luciferase Reporter Assay system, Pro-
mega) using a FLUOstar Optima fluorescence microplate reader
(BMG Labtech). All data were standardized for Renilla activity.
Results are shown as the mean6SEM of three independent
experiments, each performed in triplicate.
Far Western Analysis
Proteins were in vitro translated using the Quick Coupled
TNT in vitro transcription and translation system (Promega)
according to the manufacturer’s protocols. Equivalent amounts
of NR5A1 wildtype, NR5A1pGly35Glu, NR5A1p.Arg39Pro or
NR5A1p.Arg313Cys were fractionated on a 10% SDS-PAGE
gel and transferred to nitrocellulose membrane. The immobi-
lised proteins were treated for 10 min each at room temperature
with 6, 3, 1.5, 0.75, 0.38, and 0.19 M guanidine HCl solution
containing 20 mM HEPES (pH 7.5), 50 mM NaCl, 1 mM
EDTA, 1 mM DTT and 10% glycerol (Buffer A). Filters were
blocked for 2 hours at room temperature in buffer A +1% BSA
and then incubated with rocking overnight at 4uCw i t hin vitro
translated bait protein (GATA4 2 mg/ml) in buffer A (1% BSA
and 0.1% Tween-20). The filters were washed three times with
hybridization buffer and once with PBS-0.1% Tween-20. Bound
bait was detected with anti-bait a n t i b o d i e s ,( A b c a m ) ,f o l l o w e d
by secondary antibody conjugated with horseradish peroxidase
a n dv i s u a l i z e db yc h e m i l u m i n i s c e n c eu s i n gE C Lr e a g e n t
(Amersham).
Results
Mutations associated with 46,XY DSD
In the 11 cases of 46,XY with gonadal dysgenesis we did not
detect a mutation in the NR5A1 gene. In the 33 cases of 46,XY
DSD with ambiguous external genitalia without uterus, we
identified mutations in the NR5A1 gene in four cases (12.1%;
Table 1; Figure 1a). Case 1 carried a heterozygous T to A
mutation at position that is predicted to result in a p.Trp279Arg
amino acid change. This mutation is located in the evolutionary
conserved helix 3 of the ligand-binding domain of the protein
(Figure 1b). In silico analysis by Polyphen (http://genetics.bwh.
harvard.edu/cgi-bin/ggi/ggi.cgi) indicated that this mutation is
predicted to be highly damaging (PSIC score difference: 4.142).
His apparently healthy mother carried this mutation. Case 2
carried a heterozygote G to C transition at position that is
predicted to result in a p.Arg39Pro amino acid change within the
N-terminal zinc finger region (Figure 1c). DNA samples from the
parents of this case were unavailable for study and it is unknown if
the mutation is inherited. In this case, at 6 years of age a
laparatomy was performed that revealed bilateral testis of 20 mm
diameter. Wolffian structures such as the epididymis were also
present. The gonads were removed and the sex of rearing was
female. Gonad histology showed the presence of cord structures
with both Sertoli and Leydig cells present. Germ cells were not
observed. Case 3 carries a heterozygous frameshift mutation
c.390delG. This mutation is predicted to alter the protein
sequence and create a premature termination codon in the
mRNA at codon 295. The mother also carries the mutation and
had premature menopause at 29 years. This familial case has been
previously described (Family 4) [20]. In case 4, we identified a
Table 1. Clinical and biochemical characteristics of five 46,XY DSD patients carrying a heterozygote mutations in NR5A1.
Patient
Declared
Sex
Age at first
evaluation
Location of
Meatus Genitalia Endocrine data NR5A1 mutation
1 M 3 days Penoscrotal Ambiguous
Phallus 20610 mm
Testis 17 mm,right in
scrotum, left inguinal
Genitography: vaginal
rest 20 mm
hCG stimulation: testosterone
0.1 g–0.9 ng/ml after 361500
IU and 2.4 ng/mL after 661 500 IU
FSH 5.2 IU/L. AMH 88 pmol/L.
Inhibin B 109 pg/mL
p.Trp279Arg
2 F 6 years Penoscrotal Ambiguous, Prader III,
Phallus 20 mm,
Testis 20 mm in labia
Surgery: vaginal rest 15 mm
hCG stimulation: testosterone
0.05 g0.85 ng/mL
p.Arg39Pro
3 M 21 days Penoscrotal Ambiguous, Prader III
Phallus 15610 mm
Testes in scrotum
hCG stimulation: testosterone
0.23 g0.9 ng/mL.
Age 8.5 years, LH 0.3 IU/L,
FSH 1.8 IU/L, AMH 78 pmol/L
c.390delG
4 M 1 day Penoscrotal Ambiguous, Prader III
Phallus 1767m m
Gonads 18 mm in
scrotum
Age 2 months; testosterone
2.9 ng/mL, LH 0.76 IU/L
Age 4 months; testosterone
,0.07 ng/mL, LH 0.41 IU/L
AMH 398 pmol/L, Inhibin B
106 pg/mL
c.140_141insCACG
5 M 4 days Glandular Hypospadias
Phallus 33615 mm
Testes 18 mm in scrotum.
Testosterone 1.2 ng/ml, LH
1.6 IU/L, FSH 0.5 IU/L, AMH
175 pmol/L, Inhibin B 99 pg/mL
p.Arg313Cys
Testosterone 0–4 months 0.1–3.5 ng/mL, 4 months–11 years ,0.5 ng/mL; FSH 0–1 yr 1.5–3.5 IU/L; 1–10 yr 2.5–4.5 IU/L; LH 0–1 yr 1.5–4.5 IU/L; 1–10 yr 2–5 IU/L.
Inhibin B: 0–1 yr 94–383 pg/mL; 1–2 yr 71–204 pg/mL.
AMH,15 days 237.5+/259.2, 15 days–1 year 464.8+/292.8 pmol/L.
doi:10.1371/journal.pone.0024117.t001
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position 140 within the zinc finger domain. This frameshift
mutation is predicted to alter the protein sequence and create a
premature termination codon in the mRNA at codon 87. The
analyses of a DNA sample from the father showed a normal
NR5A1 sequence. DNA from the mother was unavailable for
study. The sequence of the SRY gene was normal in all the XY
individuals.
In the 33 cases of 46,XY DSD with hypospadias only, we
identified a single NR5A1 mutation (3%). This patient presented
with distal hypospadias, normal phallus length, and a bifid scrotum
containing testes that were normal in size and location. The
mutation consisted of a C to T transition at nucleotide position 937
that is predicted to result in a p.Arg313Cys amino acid change. This
mutation is located in the highly conserved helix 5 of the ligand-
binding domain of the protein (Figure 1b). DNA was available from
both parents and the mutation was found to be de novo. The
sequence of the SRY gene was normal in all of these cases.
These mutations were not observed in the entire coding region
of NR5A1 in 270 fertile or 358 normospermic men, indicating that
these mutations are associated with the phenotype [20], [29]. The
MAMLD1 gene on Xp28 was sequenced in 55 of the cases with
ambiguous genitalia or hypospadias [4]. No pathogenic mutations
were identified.
Plasma AMH and inhibin B concentrations
Individuals with gonadal dysgenesis showed low AMH and low
inhibin B levels consistent with the absence or reduced numbers of
Sertoli cells and germ cells that is characteristic of the dysgenetic
gonad (Fig. 2). Individuals without NR5A1 mutations and either
ambiguous external genitalia or hypospadias showed a much more
variable aspect with plasma AMH and inhibin B levels below,
within or above the normal range for age. Interestingly all
individuals carrying heterozygote NR5A1 mutations had plasma
AMH and inhibin B levels that were under or at the lower limit of
normal range irrespective of the phenotype (see also Table 1).
Figure 1. Mutations in NR5A1 associated with 46,XY DSD. (A). Distribution of NR5A1 mutations in relation to the functional domains of the
protein. The DNA-binding domain (DBD) containing two zinc-finger motifs is indicated. The FtzF1 box stabilizes protein binding to DNA. The hinge
region is important for stabilizing the ligand-binding domain and interacts with other proteins that control NR5A1 transcriptional activity. The AF2
domain recruits cofactors necessary for NR5A1 transactivating activity. (B) The sequence alignment of the distal portion of the hinge and the ligand-
binding domain (LBD) of human NR5A1 protein as compared with those of other mammals. 1 to 10 of the predicted alpha helixes in the ligand-
binding domain of NR5A1 are indicated as solid boxes, and corresponding amino acids in bold text. The position of the p.Trp279Arg and p.Arg313Cys
are highlighted. The mutations fall either in the highly conserved Helix 3 (p.Trp279Arg) or in Helix 5 (p.Arg313Cys) of the ligand-binding domain. The
mutation c.390delG was described previously [20]. (C) Evolutionary conservation of DNA binding domain of NR5A1. Sequence alignment of the
evolutionary conserved DNA-binding domain of NR5A1 showing the position of the two zinc finger domains and the p.Arg39Pro mutation.
doi:10.1371/journal.pone.0024117.g001
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activity
The c.390delG mutation that results in a premature termination
codon at amino acid position 295, predicted to be recognized by the
nonsense-mediated decay surveillance complexes and degraded.
We have previously demonstrated that even if a truncated protein
were produced, it would have severely impaired transcriptional
activity [20]. The heterozygous four base pair insertion (CACG) at
nucleotide position 140 also results in the generation of a premature
stop codon at codon position 87 and it is also predicted to undergo
nonsense-mediated decay. We observed a quantitative reduction in
the transactivation of both CYP11A1 (not shown) and AMH
promoters when assaying the effect of the NR5A1 mutants
p.Arg39Pro and p.Arg313Cys on protein function, using human
embryonic kidney HEK 293-T cells (Fig. 3). Similar to the
previously published p.Gly35Glu protein [18], the p.Arg39Pro
and p.Arg313Cys mutant proteins showed severe loss of activation.
We obtained similar results intransient gene-expressionassaysusing
the mouse embryonic stem cell line E14 (data not shown).
Mutant NR5A1 protein p.Arg39Pro and p.Arg313Cys
physically interact with GATA4
To further understand the mechanism whereby these mutations
are associated with 46,XY DSD, we investigated whether the
NR5A1 p.Arg39Pro and p.Arg313Cys mutant proteins physically
interact with a known interacting protein GATA4. GATA4
functionally interacts with NR5A1 in primary Sertoli cell cultures
and it has been shown that mutations in NR5A1 may cause 46,XY
DSD through a lack of appropriate interaction with in vitro
translated GATA4 [30], [31]. Wildtype and mutant NR5A1
proteins were fractionated on a 10% SDS-PAGE gel and
transferred to nitrocellulose membrane. The immobilised protein
was incubated with in vitro translated bait protein (GATA4) and
bound bait was detected with anti-bait antibodies, followed by
secondary antibody conjugated with horseradish peroxidase and
visualized by chemiluminiscence. In multiple experiments, the
Far-Western analyses revealed that both mutant NR5A1 proteins
retained their ability to interact with GATA4 (Figure 4).
Mutant NR5A1 proteins p.Arg39Pro and p.Arg313Cys do
not synergize with GATA4 to stimulate reporter gene
activity
It is established that GATA4 and NR5A1 transcriptionally
cooperate to synergistically activate the AMH promoter [30].
Although the mutant p.Arg39Pro and p.Arg313Cys proteins
retained their ability to physically interact with the GATA4
protein (Fig. 4), they failed to synergize with GATA4 to stimulate
AMH reporter gene activity in either HEK 293T cells (Fig. 3) or
using the murine ES cell line E14 (data available upon request).
Discussion
We have identified four novel missense and frameshift
mutations in NR5A1 associated with 46,XY DSD. All of these
Figure 2. Plasma AMH and inhibin B concentrations in each patient group. In each AMH graph the broken lines correspond to the upper
and lower limits of the normal range [22]. For inhibin B, the solid line corresponds to the median and the broken lines to the 5
th and 95
th percentiles
[23], [24]. The red asterisk indicates individuals carrying an NR5A1 heterozygote mutation and the numbers indicate the patients described in table 1.
doi:10.1371/journal.pone.0024117.g002
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either ambiguous external genitalia or distal hypospadias in one
case. Although mutations involving NR5A1 have been reported
associated with 46,XY gonadal dysgenesis in the absence of
adrenal anomalies [14], [32] our data suggest that these mutations
may be relatively uncommon in this group.
In contrast to the more severe phenotype of gonadal dysgenesis,
we identified 5 NR5A1 mutations in a heterozygous state in a series
of 66 patients with various degrees of under androgenization. One
of these cases was raised as a female whereas the other cases were
raised as male and each presented with a range of anomalies of
genital development (Table 1). We previously reported one of
these mutations, which was familial and was also associated with
ovarian insufficiency (c.390delG) [19]. In the other cases, the
p.Arg313Cys is de novo and the p.Trp279Arg mutation was carried
by the mother. The age of menopause of the mother is unknown
Figure 3. Assays of NR5A1 transactivation activity. The transcriptional activity of wild-type (WT) NR5A1 and mutant p.Gly35Glu (control) [18],
p.Arg39Pro and p.Arg313Cys were studied using the human AMH promoter in HEK293-T cells. The human AMH reporter construct was transfected
into HEK293-T cells with either the wild type or mutant NR5A1 expression vectors. Mutants p.Arg39Pro and p.Arg313Cys exhibited a dramatic
reduction in transactivation activity (blue bars). The human AMH reporter construct was transfected into HEK293-T cells with either the wild type or
mutant NR5A1 expression vector in the absence (blue) or presence (red) of the GATA4 expression vector. Data represent the mean6SEM of three
independent experiments, each performed in triplicate. Results are expressed as fold activity of the empty vector activity.
doi:10.1371/journal.pone.0024117.g003
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transmission of remaining two mutations is unknown as other
family members were not available for study.
In vitro and in vivo experiments have previously revealed that
functional cooperation between NR5A1 and a protein partner
GATA4 contribute to the proper spatiotemporal expression of the
AMH gene during the development of mammalian genitalia [30],
[31]. Our results indicate that the p.Arg39Pro and p.Arg313Cys
NR5A1 proteins associated with ambiguous genitalia and distal
hypospadias respectively showed a marked impairment of the
function of the protein. Both the mutant proteins could physically
interact with the GATA4 protein, but failed to synergise with
GATA4 to stimulate AMH reporter gene activity. It is also possible
that the phenotype could be due to a lack of synergy with SOX9 in
the control of AMH expression [13]. Previously Lin et al., reported
a boy (patient 4) with severe penoscrotal hypospadias and chordee,
a small phallus and bilateral undescended testis who carried a
heterozygous de novo L437Q NR5A1 mutation [28]. Kho ¨ler et al.,
screened the NR5A1 gene for mutations in a large series of 60
patients presenting with hypospadias. Of these 24 had mild penile
hypospadias and 36 individuals had penoscrotal hypospadias with
descended or undescended testes [19]. Three heterozygous
mutations (8%) were identified (two nonsense mutations and a
splice site mutation) in men with the more severe phenotype of
penoscrotal hypospadias, variable degrees of androgenization of
the phallus and undescended testes. Here, we have further
extended the range of phenotypes associated with NR5A1
mutations to include the milder phenotype of distal hypospadias.
We did not identify mutations in the MAMLD1 gene in a screen of
55 of the ambiguous genitalia/hypospadias cases. This is
consistent with previous reports indicating that mutations
involving MAMLD1 are rare in hypospadias [33].
Where available, serum AMH and inhibin B levels were
measured in each category of patient and compared with the
normal range for age. Individuals with hypospadias or ambiguous
external genitalia showed a wide variability in plasma concentra-
tions for age. Although the number of 46,XY individuals carrying
NR5A1 mutations in this study is limited, it is interesting to note
that each mutation is associated with plasma AMH or inhibin B
levels that are less than, or at the limits of the normal range for
age. These data suggest that the NR5A1 mutations are associated
with a primary testicular defect.
To date none of these patients have shown evidence of adrenal
insufficiency but in case 2 the gonadal histology revealed a
structurally normal testis with Leydig and Sertoli cells, although
there was a complete absence of germ cells. This is consistent with
our recent findings that mutations in NR5A1 can lead to severe
spermatogenic failure in 4% of otherwise unexplained cases of
male infertility [29]. Our data show that NR5A1 mutations can be
associated with a wide spectrum of phenotypes including distal
hypospadias and they highlight the need for a long-term follow up
of this group of patients to see if signs of adrenal insufficiency or
problems of fertility develop in later life.
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